These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19428564)

  • 21. Endocytosis targets exogenous material selectively to cathepsin S in live human dendritic cells, while cell-penetrating peptides mediate nonselective transport to cysteine cathepsins.
    Reich M; van Swieten PF; Sommandas V; Kraus M; Fischer R; Weber E; Kalbacher H; Overkleeft HS; Driessen C
    J Leukoc Biol; 2007 Apr; 81(4):990-1001. PubMed ID: 17261546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individual cathepsins degrade immune complexes internalized by antigen-presenting cells via Fcgamma receptors.
    Driessen C; Lennon-Duménil AM; Ploegh HL
    Eur J Immunol; 2001 May; 31(5):1592-601. PubMed ID: 11465117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
    Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
    Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amentoflavone and its derivatives as novel natural inhibitors of human Cathepsin B.
    Pan X; Tan N; Zeng G; Zhang Y; Jia R
    Bioorg Med Chem; 2005 Oct; 13(20):5819-25. PubMed ID: 16084098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
    Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
    Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A.
    Zaidi N; Burster T; Sommandas V; Herrmann T; Boehm BO; Driessen C; Voelter W; Kalbacher H
    Biochem Biophys Res Commun; 2007 Dec; 364(2):243-9. PubMed ID: 17937927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced antigen presentation and CTL activity by transduction of mature rather than immature dendritic cells with octaarginine-modified liposomes.
    Homhuan A; Kogure K; Nakamura T; Shastri N; Harashima H
    J Control Release; 2009 May; 136(1):79-85. PubMed ID: 19344678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cathepsin S inhibitors as novel immunomodulators.
    Thurmond RL; Sun S; Karlsson L; Edwards JP
    Curr Opin Investig Drugs; 2005 May; 6(5):473-82. PubMed ID: 15912960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions.
    Stelekati E; Bahri R; D'Orlando O; Orinska Z; Mittrücker HW; Langenhaun R; Glatzel M; Bollinger A; Paus R; Bulfone-Paus S
    Immunity; 2009 Oct; 31(4):665-76. PubMed ID: 19818652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-gamma regulates cathepsin G activity in microglia-derived lysosomes and controls the proteolytic processing of myelin basic protein in vitro.
    Burster T; Beck A; Poeschel S; Øren A; Baechle D; Reich M; Roetzschke O; Falk K; Boehm BO; Youssef S; Kalbacher H; Overkleeft H; Tolosa E; Driessen C
    Immunology; 2007 May; 121(1):82-93. PubMed ID: 17302735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of a novel highly sensitive activity-based probe for detection of cathepsin G.
    Zou F; Schmon M; Sienczyk M; Grzywa R; Palesch D; Boehm BO; Sun ZL; Watts C; Schirmbeck R; Burster T
    Anal Biochem; 2012 Feb; 421(2):667-72. PubMed ID: 22178917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the selective and non-selective cysteine protease inhibitors on the intracellular processing of interleukin 6 by HEPG2 cells.
    Peppard JV; Knap AK
    In Vitro Cell Dev Biol Anim; 1999 Sep; 35(8):459-64. PubMed ID: 10501085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
    Kalish RS; Koujak S
    Clin Immunol; 2004 Dec; 113(3):270-7. PubMed ID: 15507392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significant accumulations of cathepsin B and prolylendopeptidase in inflammatory focus of delayed-type hypersensitivity induced by Mycobacterium tuberculosis in mice.
    Kakegawa H; Matano Y; Inubushi T; Katunuma N
    Biochem Biophys Res Commun; 2004 Mar; 316(1):78-84. PubMed ID: 15003514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in cathepsin S inhibitor design.
    Link JO; Zipfel S
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):471-82. PubMed ID: 16889230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cathepsin B inhibitor, z-FA-FMK, inhibits human T cell proliferation in vitro and modulates host response to pneumococcal infection in vivo.
    Lawrence CP; Kadioglu A; Yang AL; Coward WR; Chow SC
    J Immunol; 2006 Sep; 177(6):3827-36. PubMed ID: 16951345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of cystatins in cells of the immune system.
    Kopitar-Jerala N
    FEBS Lett; 2006 Nov; 580(27):6295-301. PubMed ID: 17098233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visualization of time-dependent inactivation of human tumor cathepsin B isozymes by a peptidyl fluoromethyl ketone using a fluorescent print technique.
    Smith RE; Rasnick D; Burdick CO; Cho KJ; Rose JC; Vahratian A
    Anticancer Res; 1988; 8(4):525-9. PubMed ID: 3178145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligand binding but undetected functional response of FcR after their capture by T cells via trogocytosis.
    Hudrisier D; Clemenceau B; Balor S; Daubeuf S; Magdeleine E; Daëron M; Bruhns P; Vié H
    J Immunol; 2009 Nov; 183(10):6102-13. PubMed ID: 19841164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.